Intomics, Actelion Team on Neurodegenerative Diseases Research | GenomeWeb

NEW YORK (GenomeWeb) – Swiss contract research firm Intomics said today that it has inked an agreement to collaborate with Actelion Pharmaceuticals on research into neurodegenerative diseases.

Intomics said that the partners will apply a systems biology approach to gain a better understanding of the pathological processes underlying human neurodegenerative diseases at the molecular level with a long-term goal of facilitating better treatments for patients with such diseases.

Terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.